The editor isn't obsolete. The job description is.
Not reassuring but maybe the beginnings of a map
The mechanical layer of copy editing is being automated. Not eventually, not in theory — right now, inside live MLR workflows at major pharma companies. If you copy edit communications for a living, some of what you do today is being done by software. The rest will be, soon.
That is the honest starting point. What follows is not an argument that editors are irreplaceable. Some are. Some won’t be. The purpose here is to be specific about which is which — and what the people on the wrong side of that line can do about it.
What is actually being automated
The pre-MLR check is the clearest example. Tools are now scanning drafts before they reach human reviewers — flagging unapproved claims, checking references against source material, identifying consistency errors, tagging language that doesn’t match the approved claims library. Tasks that used to sit with a skilled editor for hours.
Indegene and Vodori are doing this at scale. Some pharma companies have reduced MLR submission timelines by 50–65% through AI-enabled workflow redesign. The content volume coming through those workflows is up 29% year-on-year. Headcount is not keeping pace.
This is not speculation. This is current operations at the companies that employ most of the people reading this.
Emma Hyland at the Veeva Commercial Summit on AI, content volume, and what it means for review. 1:26.
The work being automated is the mechanical layer: grammar, consistency, style guide compliance, reference checking, claim-flagging against an approved list. It is also, for many copy editors, the majority of their billable hours.
Tools doing this work now: Indegene AI for MLR · Vodori Pepper Flow · Veeva Vault PromoMats · Writer.com · Grammarly Business
What is not being automated
The layer that survives is judgment at the point of consequence — where being wrong has a real cost.
In MedComms, that means: Does this claim hold up against the clinical data? Is this the right framing for this efficacy result with this audience? Is the language compliant not in a generic sense, but in the specific regulatory context of this product in this market?
AI tools hallucinate. In a general context, a hallucinated fact is embarrassing. In a pharma communications context, it is a material risk. The failure modes are bad enough, the accountability clear enough, that human judgment stays in the loop — and will for the foreseeable future.
There is also the layer that is harder to articulate but equally real: knowing when to break the rule. AI applies rules. It does not transcend them. It produces averaged prose. A voice that belongs to someone — a writer, a brand, a scientific communicator with a particular way of handling uncertainty — is something AI consistently flattens. The distinction matters in any piece of communications that is trying to do something other than merely comply.
The Chartered Institute of Editing and Proofreading has developed a practical framework for mapping which editorial tasks AI can and cannot do reliably. It is worth reading in full.
“Will AI Take Our Editing & Proofreading Jobs?” — a balanced 3-minute take on where the real threat sits and where it doesn’t. 3:03.
The pivot: four paths, none of them easy
There will be fewer copy editors in this industry in ten years than there are now.
The Bureau of Labor Statistics projects 1% growth in editor roles through 2034. Before you set that number down: it’s wrong for this industry, and it’s probably wrong for most. BLS projections are built from employer surveys and historical employment trends — rearview-mirror statistics by design. They didn’t predict the collapse of newspaper newsroom employment, which shed more than half its workforce between 2008 and 2020. They don’t incorporate the AI displacement analysis that Goldman Sachs, McKinsey, and Oxford Economics have been publishing since 2023 — all of which identify content production and editorial tasks as among the most exposed to automation. And they lump “editors” into a category so broad — book editors, magazine editors, podcast producers, food bloggers, corporate communications writers — that it captures nothing useful about any of them. The number is measuring a different profession with a methodology built for a different era.
The signals from inside this one point the other way. Major pharma companies cut more than 22,000 roles in 2025 — and that was before the £300bn patent cliff fully hits. When clients cut headcount they cut agency spend, and agency spend cuts fall on production roles first. When internal pharma teams adopt AI tools for content production, agency spend drops 25–70%. The AMWA is running webinars on how medical writing careers are shifting. They wouldn’t bother if people weren’t anxious.
But the people who remain in this one will be doing work that matters more. And the people who move now will be better placed than those who wait. Here are the four pivots that are real.
1. The validator role
As AI generates first drafts at scale, someone has to own the quality framework — not fixing individual sentences, but designing and maintaining the standards AI output is checked against. This is an editorial function. It requires everything a good editor already knows, expressed as governance rather than a red pen. The AI-aware editor is a role being created right now inside large pharma content teams. It is not a downgrade. It is a different application of the same expertise.
2. The prompt architect
Writing the instructions that generate consistent, on-brand, compliant first drafts. Editors already know what good looks like — this is expressing that knowledge as a system rather than a correction. It is a closer translation of existing editorial skills than it first appears. Tredence’s prompt engineering overview is a useful primer; skip the generic sections and focus on domain-specific prompt design. The people who will do this well in MedComms are editors, not engineers.
3. The scientific editorial specialist
The intersection of scientific accuracy and regulatory compliance is the one layer that gets harder to automate, not easier. If you can read a clinical paper, understand what it does and does not show, and judge whether a piece of communications faithfully represents it — that skill is worth more per head now than it was two years ago. Envision Pharma Group’s 2026 analysis is specific about where human scientific judgment remains critical in the AI-augmented workflow. There will be fewer of these roles than there were general copy editors. They will be better paid and harder to automate.
4. Content strategy
Editorial judgment applied upstream — to which content should exist, not whether it’s correct. Harder to transition into without a track record, but the natural destination for senior editors whose production role is being compressed. The Digital Content Next analysis of AI and editorial authority is clear on how the upstream role is being reframed in professional publishing. The MedComms version of this is not yet well-defined, which is both the risk and the opportunity.
The honest closing
Most writing about editors and AI tries to reassure. This is not that.
The mechanical layer is going. The judgment layer is not. But there is less room for people who live only in the mechanical layer, and the transition is happening faster than most editorial teams are acknowledging internally.
The question for anyone in this profession right now is not whether AI is a threat. It is which part of your skill set lands on the right side of the line — and what you are building toward the other side.
Further reading and tools
On the MLR workflow shift
On what editing actually is — and what AI can’t do
On the pivot